Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hermine Brunner

Pediatric Rheumatology Cincinnati, OH Medical Doctor

NPI 1124011259 CMS profile 322493

3333 Burnet Ave, Mlc 4010, Cincinnati, OH 45229

Open in the dashboard

General payments

$531,061

303 records reported · program years 2019–2025

Research payments

$30,800

Paid to them · 34 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,858,405 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Hermine Brunner of Cincinnati, OH is reported in the CMS Open Payments database as having received $531,061 across 303 general payments and $30,800 in research payments paid to them. Separately, studies naming them as principal investigator received $4,858,405 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatric Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,548 33
2025 Research $3,755 3
2024 General $33,013 31
2024 Research $7,670 4
2023 General $27,253 34
2023 Research $6,214 4
2022 General $187,265 38
2022 Research $1,270 2
2021 General $108,625 28
2021 Research $4,520 6
2020 General $48,617 36
2020 Research $6,623 8
2019 General $109,739 103
2019 Research $748 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hermine Brunner
  • Pediatric Rheumatology median
  • Middle half of Pediatric Rheumatology
  • National median

In program year 2025, general payments to Hermine Brunner were reported at $16,548. Among 204 Pediatric Rheumatology profiles paid that year, the median was $146 and the middle half received between $95 and $522.

Show as a table
Year Hermine Brunner Pediatric Rheumatology median Middle half National median
2019 $109,739 $141 $61–$1,029 $163
2020 $48,617 $113 $33–$419 $114
2021 $108,625 $189 $61–$1,640 $132
2022 $187,265 $120 $28–$404 $149
2023 $27,253 $97 $41–$222 $160
2024 $33,013 $139 $48–$606 $164
2025 $16,548 $146 $95–$522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $208,819 77 payments
  2. Janssen Research & Development, LLC $139,158 30 payments
  3. Novartis Pharmaceuticals Corporation $30,735 37 payments
  4. Genentech USA, Inc. $27,298 25 payments
  5. GlaxoSmithKline, LLC. $22,452 31 payments
  6. E.R. Squibb & Sons, L.L.C. $19,979 16 payments
  7. Eli Lilly and Company $19,556 18 payments
  8. Novartis Pharma AG $14,720 3 payments
  9. EMD Serono, Inc. $8,348 3 payments
  10. AstraZeneca UK Limited $7,958 5 payments
  11. Other $32,039 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $433,013 149 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $51,502 22 payments
  3. Honoraria $24,625 8 payments
  4. Travel and Lodging $17,918 29 payments
  5. Food and Beverage $3,424 93 payments
  6. Education $579 2 payments
Products named General payments · program years 2019–2025
  1. XELJANZ $183,089 73 payments
  2. Actemra $34,552 29 payments
  3. STELARA $30,070 23 payments
  4. BENLYSTA $22,452 31 payments
  5. COSENTYX Immunology $11,106 4 payments
  6. ILARIS Immunology $9,746 12 payments
  7. ILARIS Immunology $7,947 4 payments
  8. COSENTYX Dermatology $7,087 1 payment
  9. Cimzia $6,903 4 payments
  10. OFEV $5,577 1 payment
  11. Other $11,787 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $26,620 21 payments
  2. F. Hoffmann-La Roche AG $2,211 11 payments
  3. Novartis Pharmaceuticals Corporation $1,744 1 payment
  4. Ucb SA $225 1 payment

Records

337 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Rheumatology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record